Bayer Joins Merck in Fighting Generic Drugs Case

For more than a decade, drugmakers have battled U.S. Federal Trade Commission accusations that they have colluded to forestall the introduction of dozens of generic medicines, costing buyers as much as $3.5 billion a year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.